Article Text

Download PDFPDF
Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort
  1. Sandra Rotea-Salvo1,
  2. Alejandro Martínez-Pradeda1,
  3. Carla Fernández-Oliveira1,
  4. Victor Giménez-Arufe1,
  5. Vanesa Balboa-Barreiro2,
  6. Luis Margusino-Framiñán1,3,
  7. Álvaro Mena-De-Cea3,4,
  8. Pilar Vázquez-Rodríguez3,4,
  9. Ángeles Castro-Iglesias3,4,
  10. Soledad López-Calvo3,4,
  11. Isabel Martín-Herranz1,
  12. Enrique Míguez-Rey3,4,
  13. Purificación Cid-Silva1,3
  1. 1Service of Pharmacy, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña, Galicia, Spain
  2. 2Clinical Epidemiology and Biostatistics Unit, Biomedical Research Institute of A Coruña (INIBIC), Universitary Hospital of A Coruña (CHUAC), SERGAS. University of A Coruña (UDC), A Coruña, Galicia, Spain
  3. 3Division of Clinical Virology, Biomedical Research Institute of A Coruña (INIBIC), Universitary Hospital of A Coruña (CHUAC), SERGAS. University of A Coruña (UDC), A Coruña, Galicia, Spain
  4. 4Service of Infectious Internal Medicine, Universitary Hospital of A Coruña (CHUAC), SERGAS, A Coruña, Galicia, Spain
  1. Correspondence to Purificación Cid-Silva, Service of Pharmacy, Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain; purificacion.cid.silva{at}sergas.es

Abstract

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) and dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) are currently available for HIV patients.

Objectives This study evaluated modifications in the renal safety profile in a large real‐world cohort of patients who had received EVG/c/FTC/TAF or DTG/ABC/3TC.

Methods A retrospective observational study of HIV-infected patients who received EVG/c/FTC/TAF or DTG/ABC/3TC between March 2015 and June 2019 at a reference hospital in north-western Spain was conducted. Epidemiological, clinical, immunovirological data and information regarding antiretroviral therapy were recorded. The statistical differences between treatments were calculated.

Results A total of 457 patients were evaluated, 266 using EVG/c/FTC/TAF and 191 using DTG/ABC/3TC. Up to week 120, serum creatinine improved in both study groups among experienced patients (EVG/c/FTC/TAF 1.01±0.24 vs 0.91±0.19, p<0.001; DTG/ABC/3TC 1.08±0.24 vs 1.02±0.31, p<0.001), while in naïve patients serum creatinine remained stable compared with baseline. Statistically significant differences were found in serum creatinine when comparing both treatments at week 48 in experienced (0.94±0.21 vs 1.09±0.28, p<0.001) and naïve patients (0.89±0.16 vs 1.06±0.20, p=0.001), and among experienced patients at week 120 (0.91±0.19 vs 1.02±0.31, p=0.015) for the EVG/c/FTC/TAF and DTG/ABC/3TC groups, respectively. During the follow-up, 39 patients in EVG/c/FTC/TAF and 33 in DTG/ABC/3TC (p=0.449) discontinued treatment. The main reason for stopping treatment was adverse events, which were similar in both groups.

Conclusions During the follow-up, patients experienced changes that were not clinically relevant in both treatment groups. Differences in renal events were not found.

  • drug-related side effects and adverse reactions
  • safety
  • clinical medicine
  • HIV
  • laboratories
  • hospital

Data availability statement

Data are available upon reasonable request.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.